CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: These data suggest that Tnfrsf4 may serve as a target to selectively eliminate/inactivate Tregs in CML without directly affecting CD8+ CTL–mediated immunity and leukemia cells.